Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

News

WilmerHale client Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced the pricing of a registered underwritten public offering of 3,902,439 shares of its common stock at a price to the public of $10.25 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $40 million.

The WilmerHale deal team representing Karyopharm includes Steven Singer, Jason Kropp, Craig Hilts and Alex Civetta.

Read Karyopharm Therapeutics' press release for more information.